Skip to content

H.R. 3810 · 118th Congress (2023–2025)

Drug Origin Transparency Act of 2023

This bill requires drug manufacturers to report on the suppliers of ingredients used in their products.

Specifically, drug manufacturers must report information relating to the supply chain of their products, including the suppliers of active ingredients and the amount of drugs that are manufactured using those ingredients. Drug manufacturers must also include information about the manufacturers of ingredients on the labels of their products.

Show official title

To amend the Federal Food, Drug, and Cosmetic Act to enhance drug manufacturing amount information reporting, and for other purposes.

Expired in House committee

Derived from the legislative history, not an official disposition.

Latest actionReferred to Health

This bill’s path

This is H.R. 3810’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced

  2. Passed House

  3. Passed Senate

  4. Sent to President

  5. Signed into law

  6. Expired

Sponsor
Rep. Anna G. Eshoo (D-CA-16)
Cosponsors
4 cosponsors

0 original · 4 later

  1. Rep. Angie Craig (D-MN-2)· Later · Jul 11, 2023
  2. Rep. John P. Sarbanes (D-MD-3)· Later · Jul 11, 2023
  3. Rep. Scott H. Peters (D-CA-50)· Later · Jul 25, 2023
  4. Rep. Tony Cárdenas (D-CA-29)· Later · Sep 13, 2023
Policy area
Health
Subjects
  • Consumer affairs
  • Government information and archives
  • Manufacturing
  • Prescription drugs

On this page

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

  1. Introduced in House

    Document: Introduced in House

    Sources
  2. Latest
    ▸ 2 committee actions · Jun 5, 2023 – Jun 9, 2023
    1. Referred to committee

      Referred to the House Committee on Energy and Commerce.

      Sources
    2. Referred to Health

      Referred to the Subcommittee on Health.

      Sources
  3. Expired

    Introduced → Referred to House Health → No further action before the 118th Congress ended.

Committees

  1. HouseEnergy and CommerceReferred Jun 5, 2023
  2. HouseHealthReferred Jun 9, 2023
    1. Sep 14, 2023 · Meeting

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in House
Titles (2)
  1. Drug Origin Transparency Act of 2023

    Display title, Short title · Introduced in House

  2. To amend the Federal Food, Drug, and Cosmetic Act to enhance drug manufacturing amount information reporting, and for other purposes.

    Official title · Introduced in House